MPN and GvHD | Virtual Congress | Novartis HCP

This site is for health care professionals only.

.atomic-navigation-links__li._lvl1:hover .atomic-navigation-links__ul._lvl2 { display: block; } .atomic-navigation-links__li._lvl1:hover .atomic-navigation-links__plus-expand-icon { display: none; } .atomic-navigation-links__li._lvl1:hover .atomic-navigation-links__minus-expand-icon { display: block; }

Pipeline Navigator

Pipeline Navigator

Disease Education

Disease Education Clinical Trials

.atomic-select.jsAtomicSelect { display: none; }

Disease Education

Disease Education Clinical Trials

Reimagining Medicine for Patients With MPN & GvHD

Striving for Optimal Clinical Outcomes for Patients with MPNs and GvHD to Potentially Change the Course of Their Disease

Explore Clinical Trials

Explore Clinical Trials

MPN

ADORE

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.

MOA data are based on in vitro/in vivo data.

Novartis

.lazy { display: none; }

Use of website is governed by the Terms of Use and Privacy Policy.

Copyright © 2022 Novartis AG. All rights reserved.

4/22 121333-2